BioCentury | Nov 26, 2018
Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Inflammation

...cell-penetrating peptide from the N-terminus of Drosophila antennapedia (Antp) and an LTBR-binding motif found in TRAF2...
...models of contact hypersensitivity. TARGET/MARKER/PATHWAY: Lymphotoxin β receptor (LTBR); tumor necrosis factor receptor-associated factor 2 (TRAF2...
...University of Maryland School of Medicine, Baltimore, Md. email: jbromberg@som.umaryland.edu Chris Lieu University of Maryland Lymphotoxin beta receptor (LTBR) Tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) Tumor...
BioCentury | Jan 2, 2018
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse and cell culture studies suggest inhibiting RAC1 or its activator TRAF6 could help treat stroke. In brain samples from a mouse model of stroke, levels of TRAF6 and activated RAC1 were higher...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting TIFA could help treat AML. In peripheral blood mononuclear cells (PBMCs) from AML patients, levels of TIFA were higher in than...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: TRAF2 and NCK interacting kinase (TNIK)

...the safety of NCB-0846. Carna Biosciences Inc. has NCB-0846 in preclinical testing for cancer. TARGET/MARKER/PATHWAY: TRAF2...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
BioCentury | May 7, 2015
Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)

Cancer INDICATION: B cell lymphoma In vitro, mouse and patient sample studies suggest inhibiting MAP3K14 could help treat diffuse large B cell lymphoma (DLBCL). Of 119 DLBCL patient samples, 15% had inactivating mutations in TRAF3...
BioCentury | Feb 27, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...In a mouse model of diet-induced obesity, selective mutation of Cd40 binding sites specific for Traf2...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Hypoxia-inducible factor 1a subunit inhibitor (HIF1AN; FIH1); hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1) In vitro and mouse studies suggest inhibiting HIF1AN and...
BioCentury | Jun 28, 2012
Distillery Therapeutics

Indication: Cancer

...sample studies suggest inhibiting TRAF2 could help treat colon cancer. In samples from 40 patients, TRAF2...
...RNA against Traf2 decreased tumor growth compared with control shRNA. Next steps include determining whether TRAF2...
Items per page:
1 - 10 of 24